GlaxoSmithKline (GSK) has asked government healthcare officials from several nations for opinions on which investigational drugs should be prioritised

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1646, 2008-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GlaxoSmithKline (GSK) have asked government healthcare officials from several nations for opinions on which investigational drugs should be prioritised

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 558, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline's candidate paediatric pneumococcal vaccine GSK 1024850A [Synflorix] has the potential to offer increased protection

By  

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline (GSK), in consultation with Health Canada, has issued a precautionary recall of one lot of Infanrix Hexa

By  

Reactions Weekly, Vol. 1, Iss. 1428, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline (GSK) has discontinued enrolment into its phase III trial of the HIV entry inhibitor, aplaviroc [GW 873140]

By  

Reactions Weekly, Vol. 1, Iss. 1076, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline has been granted priority review status in Japan for adefovir dipivoxil [Hepsera; licensed from Gilead Sciences]

By  

Inpharma, Vol. 1, Iss. 1437, 2004-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite